Zynerba Pharmaceuticals (NASDAQ:ZYNE) Downgraded by BidaskClub to Buy

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday, May 29th, BidAskClub reports.

ZYNE has been the subject of several other research reports. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Friday, March 22nd. Cantor Fitzgerald restated a “buy” rating and set a $11.00 price target on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. HC Wainwright reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, March 18th. Finally, Roth Capital began coverage

... read more at: https://techknowbits.com/2019/06/13/zynerba-pharmaceuticals-zyne-cut-to-buy-at-bidaskclub.html